$RENB
RENOVARO INC. Stock $renb

$renb Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000173112224000248 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.452M	$3.616M	$4.013M
YoY Change	69.98%	-9.88%	-3.41%
% of Gross Profit
Research & Development	$1.087M	$620.5K	$326.0K
YoY Change	354.62%	90.37%	-84.8%
% of Gross Profit
Depreciation & Amortization	$30.31K	$33.16K	$28.84K
YoY Change	7.3%	14.97%	-9.32%
% of Gross Profit
Operating Expenses	$17.19M	$4.270M	$4.368M
YoY Change	323.06%	-2.24%	-31.01%
Operating Profit	-$17.19M	-$4.270M	-$4.368M
YoY Change	323.06%	-2.24%	-31.01%
Interest Expense	$303.8K	-$259.0K	$92.89K
YoY Change	148.43%	-378.86%	-209.43%
% of Operating Profit
Other Income/Expense, Net	$166.4K	-$259.0K	-$89.88K
YoY Change	-162.84%	188.21%	-46.26%
Pretax Income	-$17.02M	-$4.529M	-$4.458M
YoY Change	293.33%	1.6%	-32.28%
Income Tax
% Of Pretax Income
Net Earnings	-$17.02M	-$4.529M	-$4.458M
YoY Change	293.33%	1.6%	-32.28%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.16	-$0.07	-$0.08
Diluted Earnings Per Share	-$0.16	-$0.07	-$0.08
COMMON SHARES
Basic Shares Outstanding	143.7M shares	66.70M shares	55.51M shares
Diluted Shares Outstanding	107.5M shares	65.85M shares	55.51M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$312.7K	$244.0K	$4.119M
YoY Change	-89.39%	-94.08%	-69.95%
Cash & Equivalents	$312.7K	$244.0K	$4.119M
Short-Term Investments
Other Short-Term Assets	$907.2K	$1.086M	$1.271M
YoY Change	-7.32%	-14.56%	39.53%
Inventory
Prepaid Expenses
Receivables		$1.074M
Other Receivables		$0.00
Total Short-Term Assets	$1.220M	$2.403M	$5.389M
YoY Change	-68.93%	-55.41%	-63.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$488.9K	$496.9K	$555.9K
YoY Change	-7.62%	-10.62%	-71.73%
Goodwill	$164.2M	$11.64M	$11.64M
YoY Change	1310.54%	0.0%
Intangibles			$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$210.6M	$55.12M	$74.33M
YoY Change	183.5%	-25.85%	235937.71%
Total Long-Term Assets	$211.1M	$55.61M	$74.88M
YoY Change	182.15%	-25.73%	-55.56%
TOTAL ASSETS
Total Short-Term Assets	$1.220M	$2.403M	$5.389M
Total Long-Term Assets	$211.1M	$55.61M	$74.88M
Total Assets	$212.3M	$58.02M	$80.27M
YoY Change	169.63%	-27.72%	-56.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.991M	$5.578M	$4.555M
YoY Change	78.71%	22.45%	2631.77%
Accrued Expenses	$3.755M	$783.6K	$932.6K
YoY Change	532.44%	-15.98%	15.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.119M	$6.509M	$4.726M
YoY Change	18.64%	37.72%	-0.03%
Total Short-Term Liabilities	$20.87M	$13.76M	$11.29M
YoY Change	77.3%	21.84%	82.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.200M
YoY Change		-100.0%	0.0%
Other Long-Term Liabilities	$20.03M	$664.2K	$882.3K
YoY Change	2316.15%	-24.72%	-91.28%
Total Long-Term Liabilities	$22.81M	$664.2K	$2.082M
YoY Change	2650.77%	-68.1%	-81.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.87M	$13.76M	$11.29M
Total Long-Term Liabilities	$22.81M	$664.2K	$2.082M
Total Liabilities	$43.68M	$14.42M	$13.37M
YoY Change	246.63%	7.84%	-23.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$274.8M	-$257.7M	-$216.5M
YoY Change	24.42%	19.04%
Common Stock	$14.75K	$6.724K	$5.572K
YoY Change	154.31%	20.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$168.6M	$43.60M	$66.90M
YoY Change
Total Liabilities & Shareholders Equity	$212.3M	$58.02M	$80.27M
YoY Change	169.63%	-27.72%	-56.17%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$17.02M	-$4.529M	-$4.458M
YoY Change	293.33%	1.6%	-32.28%
Depreciation, Depletion And Amortization	$30.31K	$33.16K	$28.84K
YoY Change	7.3%	14.97%	-9.32%
Cash From Operating Activities	-$2.634M	-$3.144M	-$3.385M
YoY Change	-20.38%	-7.12%	-26.74%
INVESTING ACTIVITIES
Capital Expenditures	$5.300K	$41.58K	$23.63K
YoY Change		75.96%
Acquisitions
YoY Change
Other Investing Activities	-$86.30K	-$13.63K
YoY Change
Cash From Investing Activities	-$91.60K	-$55.21K	-$23.63K
YoY Change		133.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.641M	2.850M	-466.6K
YoY Change	25.25%	-710.71%	-115.81%
NET CHANGE
Cash From Operating Activities	-2.634M	-3.144M	-3.385M
Cash From Investing Activities	-91.60K	-55.21K	-23.63K
Cash From Financing Activities	2.641M	2.850M	-466.6K
Net Change In Cash	-84.36K	-349.4K	-3.875M
YoY Change	-92.97%	-90.98%	132.08%
FREE CASH FLOW
Cash From Operating Activities	-$2.634M	-$3.144M	-$3.385M
Capital Expenditures	$5.300K	$41.58K	$23.63K
Free Cash Flow	-$2.639M	-$3.185M	-$3.408M
YoY Change	-20.22%	-6.54%	-26.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001527728
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2022Q4	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q4	RENB	Restricted Shares Issued For Advisory Services RestrictedSharesIssuedForAdvisoryServices		usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	RENB	Restricted Shares For Services Rendered RestrictedSharesForServicesRendered		usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	RENB	Shares In Lieu Of Interest On Million Notes Payable Extension SharesInLieuOfInterestOnMillionNotesPayableExtension		usd
	RENB	Common Shares Issued For Contingent Earn Out Liability CommonSharesIssuedForContingentEarnOutLiability		usd
	RENB	Conversion Of Note Payable For Issuance Of Preferred Stock ConversionOfNotePayableForIssuanceOfPreferredStock		usd
	RENB	Debt Discount Related To Convertible Promissory Notes DebtDiscountRelatedToConvertiblePromissoryNotes		usd
	RENB	Debt Discount Related To Million Notes Payable DebtDiscountRelatedToMillionNotesPayable		usd
	RENB	Debt Discount Related To Million Note Payable DebtDiscountRelatedToMillionNotePayable		usd
	RENB	Period Change PeriodChange		usd
CY2023Q4	us-gaap	Sublease Income SubleaseIncome		usd
	us-gaap	Sublease Income SubleaseIncome		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38758
	dei	Entity Registrant Name EntityRegistrantName	Renovaro Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2559340
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2080 Century Park East
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 906
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90067
	dei	City Area Code CityAreaCode	(305)
	dei	Local Phone Number LocalPhoneNumber	918-1980
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	RENB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	143668372	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	243980	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1874480	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1073625	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1085545	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	690925	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2403150	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2565405	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	496896	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508989	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32641	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	11640000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	11640000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	21742	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	21741	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	812691	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	913985	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55118074	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55226402	usd
CY2023Q4	us-gaap	Assets Assets	58018120	usd
CY2023Q2	us-gaap	Assets Assets	58300796	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5577917	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5296823	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	783601	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	723173	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	669384	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	184733	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	218085	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	193422	usd
CY2023Q4	RENB	Notes Payable Net NotesPayableNet	3940000	usd
CY2023Q2	RENB	Notes Payable Net NotesPayableNet	4624947	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2569379	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13758366	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11023098	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	664218	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	775587	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	664218	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	775587	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14422584	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11798685	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	561010	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	561010	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	56	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67224089	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67224089	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63698144	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63698144	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6724	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6371	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	301349389	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290554875	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257733402	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244029253	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27231	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29882	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	43595536	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46502111	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58018120	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58300796	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3616392	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4013063	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11906602	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8569903	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	620521	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	325959	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1187165	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2931334	usd
CY2023Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33162	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28844	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	60422	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	57245	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	4270075	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	4367866	usd
	us-gaap	Operating Expenses OperatingExpenses	13154189	usd
	us-gaap	Operating Expenses OperatingExpenses	11558482	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4270075	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4367866	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13154189	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11558482	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-120018	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419182	usd
CY2023Q4	us-gaap	Interest Expense Other InterestExpenseOther	274984	usd
CY2022Q4	us-gaap	Interest Expense Other InterestExpenseOther	92892	usd
	us-gaap	Interest Expense Other InterestExpenseOther	454255	usd
	us-gaap	Interest Expense Other InterestExpenseOther	188477	usd
CY2023Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	15938	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3010	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	24313	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	8633	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-259046	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-89882	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-549960	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-599026	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4529121	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-4457748	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13704149	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12157508	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65852497	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65852497	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55509239	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55509239	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65166625	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65166625	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55304356	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55304356	shares
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4529121	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-4457748	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13704149	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12157508	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-37252	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-7915	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-2651	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-161	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4491869	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4449833	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13701498	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12157347	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46502111	usd
CY2023Q3	RENB	Issuance Of Preferred Stock And Warrants In Private Placement IssuanceOfPreferredStockAndWarrantsInPrivatePlacement	2000000	usd
CY2023Q3	RENB	Issuance Of Preferred Stock And Warrants For Conversion2 Million Note IssuanceOfPreferredStockAndWarrantsForConversion2MillionNote	2000001	usd
CY2023Q3	RENB	Restricted Shares Issued For Services Rendered Value RestrictedSharesIssuedForServicesRenderedValue	4470000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	983829	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9175028	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-34601	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	46746312	usd
CY2023Q4	RENB	Stock Issued Pursuant To Warrants Exercised Value StockIssuedPursuantToWarrantsExercisedValue	341865	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	999228	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4529121	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	37252	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	43595536	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	72618848	usd
CY2022Q3	RENB	Stock Issued Pursuant To Warrants Exercised Value StockIssuedPursuantToWarrantsExercisedValue	1625000	usd
CY2022Q3	RENB	Shares Issued For Earnout SharesIssuedForEarnout	2762500	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1026008	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7754	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	70324842	usd
CY2022Q4	RENB	Shares Issued In Lieu Of Interest On1.2 Million Note Payable Extension SharesIssuedInLieuOfInterestOn1.2MillionNotePayableExtension	204392	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	819955	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-4457748	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7915	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66899356	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13704149	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12157508	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	60422	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	57245	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-120018	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419182	usd
	RENB	Non Cash Compensation NonCashCompensation	1983057	usd
	RENB	Non Cash Compensation NonCashCompensation	1845963	usd
	RENB	Restricted Shares For Services Rendered RestrictedSharesForServicesRendered	4470000	usd
	RENB	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	364415	usd
	RENB	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	149242	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-46	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-516296	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-425233	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	281095	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3153358	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-29571	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-68554	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-18520	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	14587	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10832	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5923830	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6205145	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1073625	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41584	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23633	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1115209	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23633	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2540000	usd
	RENB	Repayment Of Finance Agreement RepaymentOfFinanceAgreement	422183	usd
	RENB	Repayment Of Finance Agreement RepaymentOfFinanceAgreement	466625	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2000000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	950000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	341865	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1625000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5409682	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1158375	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1143	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17157	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1630500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5053247	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1874480	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9172142	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243980	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4118896	usd
	us-gaap	Interest Paid Net InterestPaidNet	5256	usd
	us-gaap	Interest Paid Net InterestPaidNet	30332	usd
	RENB	Finance Agreement Entered Into In Exchange For Prepaid Assets FinanceAgreementEnteredIntoInExchangeForPrepaidAssets	906834	usd
	RENB	Finance Agreement Entered Into In Exchange For Prepaid Assets FinanceAgreementEnteredIntoInExchangeForPrepaidAssets	1139875	usd
	RENB	Shares In Lieu Of Interest On Million Notes Payable Extension SharesInLieuOfInterestOnMillionNotesPayableExtension	204392	usd
	RENB	Common Shares Issued For Contingent Earn Out Liability CommonSharesIssuedForContingentEarnOutLiability	2762500	usd
	RENB	Conversion Of Note Payable For Issuance Of Preferred Stock ConversionOfNotePayableForIssuanceOfPreferredStock	2000001	usd
	RENB	Debt Discount Related To Convertible Promissory Notes DebtDiscountRelatedToConvertiblePromissoryNotes	105263	usd
	RENB	Debt Discount Related To Million Notes Payable DebtDiscountRelatedToMillionNotesPayable	90000	usd
	RENB	Debt Discount Related To Million Note Payable DebtDiscountRelatedToMillionNotePayable	50000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257733402	usd
CY2023Q4	RENB	Working Capital Deficit WorkingCapitalDeficit	11355216	usd
CY2023Q4	RENB	Working Capital Deficit WorkingCapitalDeficit	11355216	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zwUbujWnkpJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86D_zFuDIZwAh2fg">Accounting Estimates</span> –</b> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and the fair value of equity instruments issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	91387	usd
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1526990	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	620521	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1187165	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	325959	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2931334	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18960000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42611000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	11640000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	419182	usd
CY2023Q4	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	999228	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1983057	usd
CY2022Q4	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	819955	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1845963	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-4529121	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13704149	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	243980	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257733402	usd
CY2023Q3	RENB	Promissory Notes Amount PromissoryNotesAmount	550000	usd
CY2023Q3	RENB	Promissory Notes Amount PromissoryNotesAmount	500000	usd
CY2023Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	1050000	usd
CY2023Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	1050000	usd
	RENB	Accrued Interest Rate AccruedInterestRate	0.06	pure
CY2023Q4	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	15750	usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	23625	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1073625	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1015372	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	973788	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	518476	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	464799	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	496896	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508989	usd
CY2023Q4	us-gaap	Depreciation Depreciation	27198	usd
	us-gaap	Depreciation Depreciation	53677	usd
CY2022Q4	us-gaap	Depreciation Depreciation	27338	usd
	us-gaap	Depreciation Depreciation	54253	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32641	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5964	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6745	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1507	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2993	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39676	usd
	RENB	Finite Lived Intangible Assets Period Change FiniteLivedIntangibleAssetsPeriodChange	-6745	usd
	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-290	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32641	usd
CY2023Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	54251000	usd
CY2023Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	54251000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2059	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10194	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10194	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	10194	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32641	usd
CY2017Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized.
CY2018Q2	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0403	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	123602	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	253384	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	260985	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	268815	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	45021	usd
CY2023Q4	RENB	Lessee Operating Lease Liability Sub Total Amount LesseeOperatingLeaseLiabilitySubTotalAmount	-951807	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	69504	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	882303	usd
CY2022Q2	us-gaap	Lessee Finance Sublease Residual Value Guarantee Description LesseeFinanceSubleaseResidualValueGuaranteeDescription	On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
CY2023Q2	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	139460	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	35540	usd
CY2023Q2	us-gaap	Liabilities Subject To Compromise Early Contract Termination Fees LiabilitiesSubjectToCompromiseEarlyContractTerminationFees	175000	usd
CY2023Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	60922	usd
CY2022Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	96730	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	129664	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	140660	usd
CY2022Q4	us-gaap	Sublease Income SubleaseIncome	53310	usd
	us-gaap	Sublease Income SubleaseIncome	106620	usd
CY2023Q4	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	-60922	usd
CY2022Q4	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	-43420	usd
	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	-129664	usd
	RENB	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	-34040	usd
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	62573	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	123796	usd
CY2022Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	96581	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	241042	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	140660	usd
CY2022Q4	RENB	Cash Paid For The Termination Of Lease CashPaidForTheTerminationOfLease	241042	usd
	RENB	Accrual Payments Related To Termination Of Lease AccrualPaymentsRelatedToTerminationOfLease	77242	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	560000	usd
CY2023Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	3.38
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	540000	usd
CY2023Q4	RENB	Original Issue Discount Promissory Note Percentage OriginalIssueDiscountPromissoryNotePercentage	0.05	pure
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2105263	usd
CY2023Q4	RENB	Common Stock And Receives Gross Proceeds CommonStockAndReceivesGrossProceeds	10000000	usd
CY2023Q4	RENB	Offering Price Per Share Percentage OfferingPricePerSharePercentage	0.95	pure
CY2023Q4	RENB	Debt Instruments Floor Of Per Share DebtInstrumentsFloorOfPerShare	4.50
CY2023Q4	RENB	Debt Instruments Floor Of Per Share DebtInstrumentsFloorOfPerShare	4.50
CY2022Q4	RENB	Prepayment Shares PrepaymentShares	169020	shares
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	204392	usd
CY2022Q4	us-gaap	Prepaid Interest PrepaidInterest	174090	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	30302	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1200000	usd
CY2023Q4	RENB	Amended And Restated Secured Notes Balance AmendedAndRestatedSecuredNotesBalance	0	usd
CY2023Q4	RENB	Gross Proceeds Discount Percentage GrossProceedsDiscountPercentage	0.05	pure
CY2022Q2	us-gaap	Shares Issued SharesIssued	47115	shares
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	299178	usd
CY2023Q4	RENB	Monthly Installments MonthlyInstallments	77127	usd
CY2023Q4	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	235000	usd
CY2023Q4	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	235000	usd
	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	422183	usd
CY2022Q4	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	300000	usd
	RENB	Repayment On Finance Agreement RepaymentOnFinanceAgreement	466625	usd
CY2023Q4	RENB	Interest Expense Related Parties InterestExpenseRelatedParties	0	usd
	RENB	Interest Expense Related Parties InterestExpenseRelatedParties	5256	usd
CY2023Q4	us-gaap	Interest Expense Other InterestExpenseOther	274984	usd
	us-gaap	Interest Expense Other InterestExpenseOther	454255	usd
CY2022Q4	us-gaap	Interest Expense Other InterestExpenseOther	92892	usd
	us-gaap	Interest Expense Other InterestExpenseOther	188477	usd
CY2023Q4	RENB	Common Stocks Shares Authorized CommonStocksSharesAuthorized	350000000	shares
CY2023Q2	RENB	Common Stocks Shares Authorized CommonStocksSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67224089	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67224089	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63698144	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63698144	shares
CY2022Q2	us-gaap	Purchase Obligation PurchaseObligation	20000000	usd
CY2023Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	525945	shares
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	341865	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	0	shares
	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	0	shares
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	465372	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1449201	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	819955	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1845963	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1216469	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1996039	usd
CY2018Q3	RENB	Consulting Expenses ConsultingExpenses	130000	usd
CY2019Q4	RENB	Upfront Payment UpfrontPayment	10000000	usd
CY2019Q4	RENB	Payment For Expenditures PaymentForExpenditures	760000	usd
CY2021Q3	RENB	Initial Payment InitialPayment	600000	usd
CY2021Q3	RENB	Initial Payment InitialPayment	600000	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2023Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
	RENB	Purchase Agreement Description PurchaseAgreementDescription	On January 25, 2024, the Shareholders of Renovaro approved the issuance of Renovaro Shares in connection with the Transaction and the increase in the Company’s authorized shares eligible for issuance from 110,000,000 equity shares to 360,000,000 equity shares, that includes an increase in Common Stock eligible for issuance from 100,000,000 to 350,000,000 shares, and 10,000,000 shares of preferred stock eligible for issuance.
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.13
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	2000000	usd
CY2023Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	280505	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.13
	RENB	Advisory Agreement Of Shares Vested Description AdvisoryAgreementOfSharesVestedDescription	As compensation for these services, the Company will issue Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will vest in 2026, subject to Mr. Miller’s continued service through each applicable vesting date.

Files In Submission

Name	View Source	Status
0001731122-24-000248-index-headers.html	Edgar Link	pending
0001731122-24-000248-index.html	Edgar Link	pending
0001731122-24-000248.txt	Edgar Link	pending
0001731122-24-000248-xbrl.zip	Edgar Link	pending
e5415_10q.htm	Edgar Link	pending
e5415_ex3-1.htm	Edgar Link	pending
e5415_ex31-1.htm	Edgar Link	pending
e5415_ex31-2.htm	Edgar Link	pending
e5415_ex32-1.htm	Edgar Link	pending
e5415_ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
img_002.jpg	Edgar Link	pending
img_003.jpg	Edgar Link	pending
img_004.jpg	Edgar Link	pending
img_005.jpg	Edgar Link	pending
img_006.jpg	Edgar Link	pending
img_007.jpg	Edgar Link	pending
img_008.jpg	Edgar Link	pending
img_009.jpg	Edgar Link	pending
img_010.jpg	Edgar Link	pending
img_011.jpg	Edgar Link	pending
img_012.jpg	Edgar Link	pending
img_013.jpg	Edgar Link	pending
img_014.jpg	Edgar Link	pending
img_015.jpg	Edgar Link	pending
img_016.jpg	Edgar Link	pending
img_017.jpg	Edgar Link	pending
img_018.jpg	Edgar Link	pending
img_019.jpg	Edgar Link	pending
img_020.jpg	Edgar Link	pending
img_021.jpg	Edgar Link	pending
img_022.jpg	Edgar Link	pending
img_023.jpg	Edgar Link	pending
img_024.jpg	Edgar Link	pending
img_025.jpg	Edgar Link	pending
img_026.jpg	Edgar Link	pending
img_027.jpg	Edgar Link	pending
img_028.jpg	Edgar Link	pending
img_029.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
e5415_10q_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
renb-20231231.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
renb-20231231_def.xml	Edgar Link	unprocessable
renb-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
renb-20231231_cal.xml	Edgar Link	unprocessable
renb-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RENB
RENOVARO INC. Stock $renb

2024 Q1 Form 10-Q Financial Statement

#000173112224000248 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB RENOVARO INC. Stock $renb

2024 Q1 Form 10-Q Financial Statement

#000173112224000248 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB
RENOVARO INC. Stock $renb